Abstract
Group, said these early data were very encouraging. “The results of this trial are a positive signal that prevention of RSV is achievable”, he said. “The fact that viral vector vaccines have been given safely in infants, for example in malaria, gives us reason to be optimistic.” RSV vaccine research has been severely hampered by trials in the 1960s of an inactivated vaccine, which led to enhanced disease and high rates of hospital admission after natural infection. Peter Openshaw, professor of experimental medicine at Imperial College London (London, UK), who is doing similar research, said the latest data fit well with their fi ndings and off er hope for vaccine development. “A vaccine for RSV is one of the last major challenges left for vaccinologists,” he added.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
